Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jodi L Layton

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Medicine and Health, Rhode Island|February 3, 2011
Non-AIDS defining cancersJodi L Layton, Jorge J Castillo
Rhode Island Medical Journal (2013)|May 4, 2013
Advanced blood management strategies for elective joint arthroplastyJodi L Layton, Lee E Rubin, Joseph D Sweeney
The Oncologist|December 21, 2018
Recycling Discarded Drugs: Improving Access to Oral Antineoplastic DrugsJodi L Layton, Brian Lewis, Charles Ryan, et al.
Clinical Genitourinary Cancer|September 21, 2019
High-Dose Testosterone and Radium-223 Response in Metastatic Castration-Resistant Prostate CancerBryce Raymon Christensen, Pedro C Barata, Elisa M Ledet, et al.
Clinical Genitourinary Cancer|November 14, 2022
Clinical and Genetic Analysis of Metastatic Prostate Cancer to the Central Nervous System: A Single-Institution Retrospective ExperienceAlbert Jang, Ellen B Jaeger, Elisa M Ledet, et al.
The Prostate|March 24, 2021
Family history and pathogenic/likely pathogenic germline variants in prostate cancer patientsRachel A Sabol, Elisa M Ledet, Ellen Jaeger, et al.
Clinical Genitourinary Cancer|December 12, 2019
TP53 Gain-of-Function Mutations in Circulating Tumor DNA in Men With Metastatic Castration-Resistant Prostate CancerLynne Chapman, Elisa M Ledet, Pedro C Barata, et al.
The Prostate|April 28, 2023
Comparison of circulating tumor DNA between African American and Caucasian patients with metastatic castrate-resistant prostate cancer post-abiraterone and/or enzalutamideAlbert Jang, Sree M Lanka, Minqi Huang, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Medicine and Health, Rhode Island|February 3, 2011
Non-AIDS defining cancersJodi L Layton, Jorge J Castillo
Rhode Island Medical Journal (2013)|May 4, 2013
Advanced blood management strategies for elective joint arthroplastyJodi L Layton, Lee E Rubin, Joseph D Sweeney
The Oncologist|December 21, 2018
Recycling Discarded Drugs: Improving Access to Oral Antineoplastic DrugsJodi L Layton, Brian Lewis, Charles Ryan, et al.
Clinical Genitourinary Cancer|September 21, 2019
High-Dose Testosterone and Radium-223 Response in Metastatic Castration-Resistant Prostate CancerBryce Raymon Christensen, Pedro C Barata, Elisa M Ledet, et al.
Clinical Genitourinary Cancer|November 14, 2022
Clinical and Genetic Analysis of Metastatic Prostate Cancer to the Central Nervous System: A Single-Institution Retrospective ExperienceAlbert Jang, Ellen B Jaeger, Elisa M Ledet, et al.
The Prostate|March 24, 2021
Family history and pathogenic/likely pathogenic germline variants in prostate cancer patientsRachel A Sabol, Elisa M Ledet, Ellen Jaeger, et al.
Clinical Genitourinary Cancer|December 12, 2019
TP53 Gain-of-Function Mutations in Circulating Tumor DNA in Men With Metastatic Castration-Resistant Prostate CancerLynne Chapman, Elisa M Ledet, Pedro C Barata, et al.
The Prostate|April 28, 2023
Comparison of circulating tumor DNA between African American and Caucasian patients with metastatic castrate-resistant prostate cancer post-abiraterone and/or enzalutamideAlbert Jang, Sree M Lanka, Minqi Huang, et al.
Pageof 1